spacer
home > ict > autumn 2017 > helping hands
PUBLICATIONS
International Clinical Trials

Helping Hands

To be able to discuss how site nursing support benefits
the clinical trial industry and home care in particular, the
ongoing obstacles need to be understood. Clinical trial sites
face many challenges, such as engaging minority groups
efficiently and quickly identifying patients, while coping
with increased work load due to the small pool of available
research locations.

Equal Representation

One barrier that continues to impact clinical trials is the
enrolment of ethnic minority groups. These classes remain
underrepresented in treatment experiments that could
save their lives. However, some diseases are more prevalent
in different racial and ethnic groups – African Americans
are approximately 70% more likely to be diagnosed with
diabetes, for example (1). Therefore, to produce a drug
that will best treat these patients they must be included
in clinical trials.

This remains an obstacle for several reasons: a lack of
minority principal investigators (PI), a lack of awareness
of clinical trials among these groups or patients living too
far from an enrolling location.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Helena Baker is Vice President of Nursing at Medical Research Network and has over 32 years’ experience in nursing and healthcare. She previously worked at the Royal London Hospital in Whitechapel, Ferring Pharmaceuticals Ltd and St Bartholomew’s Hospital in the UK, as well as acting as a healthcare analyst to the pharmaceutical industry.
spacer
Helena Baker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement